March 12, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score.
Schedules of Controlled Substances: Rescheduling of Marijuana
Regulatory Summary
The rescheduling of marijuana under controlled substance schedules directly affects cannabis clinicians’ prescribing authority, patient access to treatment, and research capabilities by altering legal classification and regulatory requirements.
Definition of Engaged in the Business as a Dealer in Firearms
This firearms regulation defines dealer licensing requirements and has no direct relevance to cannabis clinicians or patients, as it pertains exclusively to firearms commerce and does not intersect with cannabis medicine practice or patient care.
This DEA action schedules three synthetic opioids as Schedule I controlled substances, with no direct relevance to cannabis medicine practice or patient treatment protocols.
Regulatory Action Summary
This DEA action schedules three synthetic opioids (butonitazene, flunitazene, metodesnitazene) as controlled substances, with no direct relevance to cannabis medicine practice or patient care.
Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I
Regulatory Summary
The DEA placed 2-Methyl AP-237, a synthetic opioid analog, into Schedule I, establishing maximum criminal penalties; this action does not directly affect cannabis clinical practice or patient access.
This regulatory action schedules synthetic amphetamines (DOI and DOC), not cannabis, and has no direct relevance to cannabis clinicians or patients.
Regulatory Summary
The DEA temporarily placed six synthetic cannabinoids into Schedule I, restricting their legal availability and potentially affecting patients relying on unregulated cannabinoid products for therapeutic purposes.
Schedules of Controlled Substances: Placement of Ethylphenidate in Schedule I
Regulatory Summary
This DEA action schedules ethylphenidate (a stimulant metabolite) as a controlled substance, establishing regulatory precedent for classifying novel psychoactive compounds—potentially informing how cannabis-derived cannabinoids and synthetic analogs are evaluated.
Schedules of Controlled Substances: Placement of Metonitazene in Schedule I
Regulatory Summary
The DEA placed metonitazene, a synthetic opioid, into Schedule I, restricting its availability; this action does not directly affect cannabis clinical practice or patient access.
Regulatory Summary
The DEA temporarily placed five benzodiazepine analogues into Schedule I, restricting their legal availability—relevant to cannabis clinicians managing anxiety and sleep disorders who may have considered these as adjunctive treatments.
Importer of Controlled Substances Application Biopharmaceutical Research Company – DEA1224
Regulatory Summary
A biopharmaceutical research company applied to become a DEA-registered importer of controlled substances, potentially enabling clinical research and patient access to cannabis-derived pharmaceutical products under federal oversight.
Importer of Controlled-Bright Green(2024-20083)DEA1426
Regulatory Summary
DEA registration document (2024-20083) authorizes importation of controlled substances; clinicians and patients should verify their medication source’s legitimate DEA import licensing status.
Importer of Controlled-Cambridge Isotope(2024-20082)DEA1429
Regulatory Summary
DEA registration for Cambridge Isotope as a controlled substance importer enables sourcing of isotopically-labeled research compounds for cannabis pharmacology studies, supporting clinical research and drug development.
CMS updated 2025 physician payment policies and Part B coverage determinations, potentially affecting cannabis clinician reimbursement rates and patient access to cannabis-related medical services under Medicare and Medicaid programs.
Regulatory Summary
This proposed rule updates Medicare/Medicaid payment policies and coverage rules for 2025, potentially affecting reimbursement and clinical practice standards for cannabis-related medical services under federal healthcare programs.
Bulk Manufacturer-Royal Emerald (2024-11786) DEA1368
Regulatory Summary
DEA approval of Royal Emerald as a bulk cannabis manufacturer expands licensed production capacity, potentially increasing medicine availability and supply chain options for cannabis clinicians and patients.
Importer Controlled-VA Cooperative (2024-11795) DEA1374
Regulatory Summary
DEA Form 1374 governs importer licenses for controlled substances; this 2024 cooperative agreement affects cannabis clinicians’ and patients’ access to federally regulated cannabis products through licensed importers.
Importer Controlled- Quagen Pharma (2024-11892) DEA1381
Regulatory Summary
DEA Import Control Action 2024-11892 against Quagen Pharma restricts controlled substance importation, potentially affecting cannabis clinicians’ and patients’ access to pharmaceutical cannabinoid products and related medicines.
Exempt Chemical Preparations May 2024 (2024-10465) – DEA372
Regulatory Summary
The DEA’s May 2024 guidance on exempt chemical preparations clarifies which cannabis-derived products are exempt from Schedule I controls, affecting prescribing eligibility and patient access to certain cannabinoid formulations.
This CMS final rule establishes 2024 Medicare/Medicaid payment policies and coverage requirements; cannabis remains federally non-covered, limiting patient access and clinician reimbursement under these programs.
Digest-Level Clinical Commentary
Clinical Reflection
The predominance of synthetic cannabinoid and novel psychoactive substance scheduling in this digest, combined with the absence of substantive cannabis rescheduling implementation guidance, reflects the current regulatory reality that practitioners like myself operate within a fragmented framework where cannabis remains federally scheduled despite growing clinical evidence and state-level legalization. The concurrent focus on Medicare/Medicaid reimbursement policies suggests we should anticipate that insurance coverage questions will increasingly outpace the clinical guidance currently available for cannabis-based therapeutics. What these items collectively signal is that cannabis medicine practitioners must remain vigilant about distinguishing evidence-based cannabinoid therapeutics from uncontrolled synthetic analogs while simultaneously preparing for the administrative and billing complexities that will accompany any shifts in federal coverage policies.
Clinical Perspective
These regulatory items reflect the ongoing evolution of controlled substance scheduling, with particular attention to emerging synthetic drugs and new chemical variants that continue to challenge public health authorities. The inclusion of multiple synthetic opioids and benzodiazepine analogues suggests a persistent pattern of clandestine drug manufacturing designed to circumvent existing regulations, requiring continuous monitoring and scheduling updates. The cannabis rescheduling consideration alongside these actions indicates a broader reassessment of drug classification frameworks, while concurrent Medicare policy updates highlight the healthcare system’s need to adapt reimbursement structures as medication access and prescribing patterns continue to change.
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
